Pomalidomide-C3-CO2H is primarily utilized in the development of targeted cancer therapies, particularly for the treatment of multiple myeloma. It serves as a key intermediate in the synthesis of antibody-drug conjugates (ADCs), which are designed to deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. Its structure allows for effective conjugation with monoclonal antibodies, enhancing the precision and efficacy of the treatment. Additionally, it is explored in research for its potential in modulating the immune system and inhibiting angiogenesis, which can help in controlling tumor growth and progression. Its applications extend to preclinical studies aimed at understanding its mechanisms and optimizing its therapeutic potential in oncology.